8 results match your criteria: "Institute for Regenerative Cures (IRC)[Affiliation]"
Blood Cancer Discov
September 2021
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Unlabelled: As of April 2021, there are five commercially available chimeric antigen receptor (CAR) T cell therapies for hematological malignancies. With the current transition of CAR T cell manufacturing from academia to industry, there is a shift toward Good Manufacturing Practice (GMP)-compliant closed and automated systems to ensure reproducibility and to meet the increased demand for cancer patients. In this review we describe current CAR T cells clinical manufacturing models and discuss emerging technological advances that embrace scaling and production optimization.
View Article and Find Full Text PDFStem Cells Transl Med
September 2018
Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charite' - Universitatsmedizin Berlin, Berlin, Germany.
The aim of this study was to vascularize brain organoids with a patient's own endothelial cells (ECs). Induced pluripotent stem cells (iPSCs) of one UC Davis patient were grown into whole-brain organoids. Simultaneously, iPSCs from the same patient were differentiated into ECs.
View Article and Find Full Text PDFCell Stem Cell
October 2017
University of California, Davis, Institute for Regenerative Cures (IRC), Sacramento, CA, USA.
As genome editing rapidly progresses toward the realization of its clinical promise, assessing the suitability of current tools and processes used for its benefit-risk assessment is critical. Although current regulations may initially provide an adequate regulatory framework, improvements are recommended to overcome several existing technology-based safety and efficacy issues.
View Article and Find Full Text PDFTrends Biotechnol
July 2015
Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité University Medicine Berlin, Campus Virchow, Berlin, Germany; Department of Nephrology and Internal Intensive Care, Charité University Medicine Berlin, Campus Virchow, Berlin, Germany.
Despite undeniable accomplishments in developing cell and gene therapeutic strategies to combat HIV infection, key social, economic, and policy-related challenges still need to be overcome for any future commercialization efforts of these novel therapies to be successful. Here, we address these challenges and structure a framework for eradicating HIV/AIDS using gene therapy.
View Article and Find Full Text PDFWorld Neurosurg
November 2015
Department of Neurosurgery, UC Davis Medical Center, Sacramento, California, USA; UC Davis Stem Cell Program, Sacramento, California, USA. Electronic address:
Background: The dura mater can be easily biopsied during most cranial neurosurgical operations. We describe a protocol that allows for robust generation of induced pluripotent stem cells (iPSCs) and neural progenitors from acutely harvested dura mater.
Objective: To generate iPSCs and neural progenitor cells from dura mater obtained during ventriculoperitoneal shunt surgery.
Trends Mol Med
November 2014
Formerly Committee for Advanced Therapies, European Medicines Agency, 7, Westferry Circus E14 4HB, London, UK; Danish Health and Medicines Authority, Axel Heides Gade 1, 2300 Copenhagen, Denmark; Twincore Centre for Experimental and Clinical Infection Research, Feodor-Lynen-Straße 730625 Hannover, Germany.
During the past decade, successful gene therapies for immunodeficiencies were finally brought to the clinic. This was accomplished through new gene therapy vectors and improved procedures for genetic modification of autologous hematopoietic stem cells. For HIV, autologous hematopoietic stem cell (HSC) gene therapy with 'anti-HIV genes' promises a functional cure for the disease.
View Article and Find Full Text PDFImmunotherapy
May 2013
School of Medicine, University of California Davis, Institute for Regenerative Cures (IRC), Sacramento, CA 95817, USA.
Evaluation of: Liao H, Bonsignori M, Alam M et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38, 176-186 (2013).
View Article and Find Full Text PDF